Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2020 / Jan / Meddling with Nature
Genetics and epigenetics Biochemistry and molecular biology Technology and innovation Regulation and standards Research and Innovations

Meddling with Nature

The benefits and dangers of human germline genome editing

By Luke Turner 01/28/2020 Quick Read (pre 2022) 1 min read

Share

Human germline genome editing (hGGE) has great medical potential, especially in preventing heritable disorders; it can delete, add to, or even replace DNA sequences that are expressed in cells and passed onto the next generation. CRISPR-Cas9, the most widely used genome editing tool, targets specific DNA sequences and cuts them using the Cas9 enzyme, allowing for changes before the cell repairs the cut.

However, a new report from the UK Parliamentary Office of Science and Technology has urged caution, calling for a full review of the potential clinical effectiveness, cost-effectiveness, and risks and benefits of hGGE before deeming it safe (1). For those with serious monogenic disorders, such as cystic fibrosis, hGGE could ensure that their children won’t suffer from the same condition. But for now, at least in the UK, the Human Fertilization and Embryology Act 1990 prohibits implanting embryos with altered germline DNA inside a woman. The Human Fertilization and Embryology Authority can award licenses for research – but only for projects that involve human embryos outside the body. Safety and ethical concerns have arisen around the world; in China, for example, one scientist claimed to have edited the genome of embryos that resulted in the birth of twin girls (2).

Before hGGE can be adopted in the clinic, a number of safety issues loom large. The main concerns involve edits being made at incorrect DNA sites, or potential unintended consequences of correct edits. There’s also the possibility that a cell repairs cut DNA in an unanticipated way, or that the edited DNA sequence is absent in some cells. Genome editing techniques continue to improve – but the new report calls for further advancements before hGGE could be considered safe for clinical use.

With so many unanswered questions surrounding hGGE, some scientists want a moratorium on clinical heritable genome editing until a universal framework is established (3). Several international initiatives have already tried to address the issue – and, in 2019, the WHO launched a global registry for human genome editing that aims to track all research and make recommendations on appropriate legislation (4). Watch this space…

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. UK Parliament Post Note, “Human Germline Genome Editing” (2020). Available at: https://bit.ly/2RMSpWz.
  2. Science, “Did CRISPR help—or harm—the first-ever gene-edited babies?” (2019). Available at: https://bit.ly/38E0TWy.
  3. ES Lander et al., “Adopt a moratorium on heritable genome editing”, Nature, 567, 165 (2018). PMID: 30867611.
  4. World Health Organization, “A global observatory for gene editing” (2019). Available at: https://bit.ly/2TUKR6E.

About the Author(s)

Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

More Articles by Luke Turner

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.